Portal de Periódicos da CAPES

Failure to Comply: A Therapeutic Dilemma and the Bane of Clinical Trials

1996; Wiley; Volume: 36; Issue: 8 Linguagem: Inglês

10.1002/j.1552-4604.1996.tb04235.x

1552-4604

Milo Gibaldi,

Schizophrenia research and treatment

The Journal of Clinical PharmacologyVolume 36, Issue 8 p. 674-682 Failure to Comply: A Therapeutic Dilemma and the Bane of Clinical Trials Milo Gibaldi PhD, Corresponding Author Milo Gibaldi PhD Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington.Department of Pharmaceutics, School of Pharmacy, Box 357610, University of Washington, Seattle, WA 98195.Search for more papers by this author Milo Gibaldi PhD, Corresponding Author Milo Gibaldi PhD Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington.Department of Pharmaceutics, School of Pharmacy, Box 357610, University of Washington, Seattle, WA 98195.Search for more papers by this author First published: August 1996 https://doi.org/10.1002/j.1552-4604.1996.tb04235.xCitations: 6AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Survey by Applied Research Techniques conducted for the American Association of Retired Persons. Washington, DC: American Association of Retired Persons, 1984. Google Scholar 2 National Pharmaceutical Council: Emerging issues in pharmaceutical cost containment. Reston, VA: National Pharmaceutical Council, 1992. Google Scholar 3 National Council on Patient Information and Education: Children and America's Other Drug Problem: Guidelines for Improving Prescription Medication use among Children and Teenagers. Washington, DC: National Council on Patient Information and Education, 1989. Google Scholar 4 National Council on Patient Information and Education: Priorities and Approaches for Improving Prescription Medicine use by Older Americans. Washington, DC: National Council on Patient Information and Education, 1987. Google Scholar 5 Mackowiak ED, O'Connor TW, Thomason M, Nightswander R, Smith M, Vogenberg A, et al: Compliance devices preferred by elderly patients. Am Pharm 1984; NS34: 547–552. Google Scholar 6 Levy M, Mermelstein L, Hemo D: Medical admissions due to noncompliance with drug therapy. Int J Clin Pharmacol Ther Toxicol 1982; 20: 600–604. CASPubMedWeb of Science®Google Scholar 7 Stradberg LR: Drugs as a reason for nursing home admissions. Am Health Care Assoc J 1984; 10: 20–23. Google Scholar 8 Einarson TR: Drug-related hospital admissions. Ann Pharmacother 1993; 27: 832–840. 10.1177/106002809302700702 CASPubMedWeb of Science®Google Scholar 9 Sullivan SD, Kreling DH, Hazlet TK: Noncompliance with medication regimens and subsequent hospitalizations: a literature analysis and cost of hospitalization estimate. J Res Pharm Econ 1990; 2: 19–33. Google Scholar 10 Sumartojo E: When tuberculosis treatment fails: a social behavioral account of patient adherence. Am Rev Respir Dis 1993; 147: 1311–1320. 10.1164/ajrccm/147.5.1311 CASPubMedWeb of Science®Google Scholar 11 Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen M, Dooley SW: The emergence of drug resistant tuberculosis in New York City. N Engl J Med 1993; 328: 521–526. 10.1056/NEJM199302253280801 CASPubMedWeb of Science®Google Scholar 12 Iseman MD, Cohn DL, Sbarbaro JA: Directly observed treatment of tuberculosis. N Engl J Med 1993; 328: 576–578. 10.1056/NEJM199302253280811 CASPubMedWeb of Science®Google Scholar 13 Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, et al: The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179–1184. 10.1056/NEJM199404283301702 CASPubMedWeb of Science®Google Scholar 14 Goble M, Iseman MD, Madsen LA, Waite D, Ackerson WD, Horsburgh CR Jr: Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527–532. 10.1056/NEJM199302253280802 CASPubMedWeb of Science®Google Scholar 15 Stephenson BJ, Rowe BH, Haynes RB, Machario WM, Leon G: Is this patient taking the treatment as prescribed?. JAMA 1993; 269: 2779–2781. 10.1001/jama.1993.03500210079036 CASPubMedWeb of Science®Google Scholar 16 Mellins RB, Evans D, Zimmerman B, Clark NM: Patient compliance: are we wasting our time and don't know it?. Am Rev Respir Dis 1992; 146: 1376–1377. 10.1164/ajrccm/146.6.1376 CASPubMedWeb of Science®Google Scholar 17 Marwick C: FDA pushes for prescription drug information. JAMA 1995; 273: 1815–1816. 10.1001/jama.1995.03520470023008 CASPubMedWeb of Science®Google Scholar 18 Shaw E, Anderson JG, Maloney M, Jam SJ, Fagan D: Factors associated with noncompliance of patients taking antihypertensive medications. Hosp Pharm 1995; 30: 201–203, 206–207. PubMedGoogle Scholar 19 Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al: Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA 1986; 256: 1449–1455. 10.1001/jama.1986.03380110055026 CASPubMedWeb of Science®Google Scholar 20 Volpicelli JR: Naltrexone in alcohol dependence. Lancet 1995; 346: 456. 10.1016/S0140-6736(95)91316-5 CASPubMedWeb of Science®Google Scholar 21 Eisen SA, Miller DK, Woodward RS, Spitznagel E. Przybeck TR: The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881–1884. 10.1001/archinte.1990.00390200073014 CASPubMedWeb of Science®Google Scholar 22 Levy G: A pharmacokinetic perspective on medicament noncompliance. Clin Pharmacol Ther 1993; 54: 242–244. 10.1038/clpt.1993.143 PubMedWeb of Science®Google Scholar 23 Urquhart J: Patient compliance as an explanatory variable in four selected cardiovascular studies. In JA Cramer, B Spilker, (Eds.): Patient Compliance in Medical Practice and Clinical Trials. New York: Raven Press, 1991; 301–322. Google Scholar 24 Lurie N, Ward NB, Shapiro MF, Gallego C, Vaghaiwalla R, Brook RH: Termination of Medi-Cal benefits: a follow-up study one year later. N Engl J Med 1986; 314: 1266–1268. 10.1056/NEJM198605083141934 CASPubMedWeb of Science®Google Scholar 25 Lurie N, Ward NB, Shapiro MF, Brook RH: Termination from Medi-Cal: does it affect health?. N Engl J Med 1984; 311: 480–484. 10.1056/NEJM198408163110735 CASPubMedWeb of Science®Google Scholar 26 Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S: Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity. N Engl J Med 1987; 317: 550–556. 10.1056/NEJM198708273170906 CASPubMedWeb of Science®Google Scholar 27 Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin TJ, Choodnovskiy I: Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med 1991; 325: 1072–1077. 10.1056/NEJM199110103251505 CASPubMedWeb of Science®Google Scholar 28 Avorn J, Dreyer P, Connelly K, Soumerai SB: Use of psychoactive medication and the quality of care in rest homes: findings and policy implications of a statewide study. N Engl J Med 1989; 320: 227–232. 10.1056/NEJM198901263200406 CASPubMedWeb of Science®Google Scholar 29 Harris BL, Stergachis A, Ried LD: The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization. Med Care 1990; 28: 907–917. 10.1097/00005650-199010000-00005 CASPubMedWeb of Science®Google Scholar 30 Horwitz RI, Horwitz SM: Adherence to treatment and health outcomes. Arch Intern Med 1993; 153: 1863–1868. 10.1001/archinte.1993.00410160017001 CASPubMedWeb of Science®Google Scholar 31 The Coronary Drug Project Research Group: Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980; 303: 1038–1041. 10.1056/NEJM198010303031804 PubMedWeb of Science®Google Scholar 32 Lipid Research Clinics Program: Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365–374. PubMedGoogle Scholar 33 Horwitz R, Viscoli CM, Berkman L, Donaldson RM, Horwitz SM, Murray CJ, et al: Treatment adherence and risk of death after a myocardial infarction. Lancet 1990; 336: 542–545. 10.1016/0140-6736(90)92095-Y CASPubMedWeb of Science®Google Scholar 34 Epstein LH, Cluss PA: A behavioral medicine perspective on adherence to long-term medical regimens. J Consult Clin Psychol 1982; 50: 950–971. 10.1037/0022-006X.50.6.950 CASPubMedWeb of Science®Google Scholar 35 Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz C, Mukherjee J: Can simple clinical measurements detect patient noncompliance?. Hypertension 1980; 2: 757–764. 10.1161/01.HYP.2.6.757 CASPubMedWeb of Science®Google Scholar 36 Inui TS, Carter WB, Pecoraro RE: Screening for noncompliance among patients with hypertension: is self-report the best available measure?. Med Care 1981; 19: 1061–1064. 10.1097/00005650-198110000-00008 CASPubMedWeb of Science®Google Scholar 37 Urquhart J: Correlates of variable patient compliance in drug trials: relevance in the new health care environment. Adv Drug Res 1995; 26: 237–257. 10.1016/S0065-2490(05)80007-3 Google Scholar 38 Urquhart J: Variable patient compliance in ambulatory trials: nuisance, threat, opportunity. J Antimicrob Chemother 1993; 32: 643–649. 10.1093/jac/32.4.643 CASPubMedWeb of Science®Google Scholar 39 Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL: How often is medication taken as prescribed?. JAMA 1989; 261: 3273–3277. 10.1001/jama.1989.03420220087032 CASPubMedWeb of Science®Google Scholar 40 Rand SC, Wise RA, Nides M, Simmons MS, Bleecker ER, Kusek JW, et al: Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis 1992; 146: 1559–1564. 10.1164/ajrccm/146.6.1559 CASPubMedWeb of Science®Google Scholar 41 Pullar T, Kumar S, Tinall H, Feely M: Time to stop counting tablets?. Clin Pharmacol Ther 1989; 46: 163–168. 10.1038/clpt.1989.121 PubMedWeb of Science®Google Scholar 42 Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Teta MA, Saperia GM, Platt R: Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care setting. N Engl J Med 1995; 332: 1125–1131. 10.1056/NEJM199504273321703 PubMedGoogle Scholar 43 The Steering Committee of the Physicians' Health Study Research Group: Preliminary report: findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1988; 318: 262–264. 10.1056/NEJM198801283180431 PubMedWeb of Science®Google Scholar 44 The Writing Group for the PEPI Trial: Effects of estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199–208. PubMedWeb of Science®Google Scholar 45 The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986. 10.1056/NEJM199309303291401 PubMedWeb of Science®Google Scholar 46 Anastasio GD, Little JM Jr, Robinson MD, Pettice YL, Leitch BB, Norton HJ: Impact of compliance and side effects on the clinical outcome of patients treated with oral erythromycin. Pharmacotherapy 1994; 14: 229–234. 10.1002/j.1875-9114.1994.tb02814.x CASPubMedWeb of Science®Google Scholar 47 Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, et al: Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9: L47–L53. 10.1097/00004850-199400910-00008 PubMedWeb of Science®Google Scholar 48 Anderson IM, Tomenson BM: Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. Br Med J 1995; 310: 1433–1438. 10.1136/bmj.310.6992.1433 CASPubMedWeb of Science®Google Scholar 49 Jonsson B, Bebbington PE: What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665–673. 10.1192/bjp.164.5.665 CASPubMedWeb of Science®Google Scholar Citing Literature Volume36, Issue8August 1996Pages 674-682 ReferencesRelatedInformation